Menopause Reversal and Delay: What Is Actually Possible?
The idea of reversing or delaying menopause reversal treatment has moved from fringe science newsletters to serious academic journals, but the gap between what researchers are studying and what clinicians can actually offer remains enormous. A woman who searches for “menopause reversal” online will find clinic websites promising ovarian rejuvenation, PRP injections into her ovaries, and supplements that claim to restore her menstrual cycles. She will also find the Columbia University rapamycin trial, the ongoing work on ovarian cryopreservation for healthy women, and the AMH test that can tell her roughly how many years she has left before her final period. Sorting the real science from the marketing noise matters because the window for meaningful intervention is narrow — most of these strategies work only if you start them years before menopause actually begins.
The term “menopause reversal” itself is misleading. Menopause is not a disease that can be cured. It is the permanent end of ovarian function, defined by 12 consecutive months without a period. Once that milestone has passed, no intervention in 2025 has been shown to reliably restart ovulation and hormone production. What researchers can do is delay the onset — push menopause from age 51 to age 55, or from 48 to 52 — which, if you think about it, is a significant outcome. A five-year delay in menopause means five more years of natural estrogen protection for your bones, heart, and brain. The question is which interventions actually achieve that, which are still experimental, and which are selling false hope.
Rapamycin: The mTOR Inhibitor That Might Delay Ovarian Aging
Rapamycin is the most promising drug candidate for delaying menopause, and it emerged from an unexpected place. Rapamycin (sirolimus) is an immunosuppressant first approved in 1999 to prevent organ transplant rejection. It works by inhibiting a cellular pathway called mTOR — mechanistic target of rapamycin — which regulates cell growth, metabolism, and aging. In 2013, researchers at Novartis showed that rapamycin extended lifespan in mice by up to 25 percent. Follow-up studies found that female mice treated with rapamycin maintained ovarian function longer and had more surviving follicles at older ages. The effect was large enough that researchers started asking whether the same mechanism could apply to human ovaries.
The first human trial of rapamycin for ovarian aging launched at Columbia University in 2022, led by Dr. Yousin Suh, a professor of genetics and aging. The REPLENISH trial (Rapamycin for Enhancing and Preserving Late-life Ovarian Function and Healthspan) enrolled women aged 38 to 45 with normal ovarian function and gave them low-dose rapamycin three times per week. Preliminary results presented at the 2024 North American Menopause Society annual meeting showed that treated women had higher anti-Müllerian hormone (AMH) levels after 12 months compared to placebo — a surrogate marker suggesting slower follicle depletion. The effect was modest: AMH declined 15 percent slower in the rapamycin group. Not a reversal, not a cure, but a measurable deceleration of the ovarian clock. A follow-up study called Rapal for Women is now enrolling at multiple US centres to test whether the effect translates into a later age at final menstruation.
The catch: rapamycin is an immunosuppressant. Even at the low doses used in the REPLENISH trial — roughly one-tenth of the transplant dose — it caused mouth ulcers in 18 percent of participants, mild gastrointestinal symptoms, and a small increase in cholesterol levels. Long-term safety data in healthy premenopausal women does not exist. Rapamycin is not approved for ovarian aging by any regulatory agency. Women in the US who want to try it must find a doctor willing to prescribe it off-label, which is rare. In the UK and Australia, the drug is not available for this indication at all outside clinical trials.
Ovarian Cryopreservation: Freezing Tissue to Preserve Hormone Function
Ovarian tissue cryopreservation — freezing slices of ovarian cortex for later reimplantation — is an established technique for preserving fertility in women undergoing cancer treatment. But a small group of researchers and private clinics have started offering it to healthy women who want to delay menopause. The logic is straightforward: freeze a piece of your ovary when you are in your twenties or early thirties, when it contains hundreds of thousands of follicles. Reimplant it when you enter perimenopause, and the reimplanted tissue may resume producing estrogen and progesterone for several years, pushing back the age at which you reach natural menopause.
The data on this approach comes mostly from cancer patients who had ovarian tissue frozen before chemotherapy and then reimplanted after remission. A 2023 review in Human Reproduction Update analysed 350 reimplantation procedures worldwide and found that ovarian function returned in roughly 95 percent of cases within four to nine months. The reimplanted tissue functioned for an average of four to seven years before the follicles were depleted. These were women who had been rendered menopausal by chemotherapy — their natural ovarian function was already destroyed, so the reimplanted tissue represented their only source of estrogen. Applying the same procedure to healthy women with intact ovaries is a different proposition entirely.
Several private fertility centres in the US, including the Centre for Human Reproduction in New York, now offer “ovarian tissue cryopreservation for menopause delay” as a paid service. The cost is $8,000 to $15,000 for the harvesting and freezing, plus annual storage fees of $300 to $600. Reimplantation surgery, when the woman reaches perimenopause, costs another $8,000 to $12,000. The total bill: $16,000 to $30,000 for a procedure that might give you four to seven years of delayed menopause. There are no long-term follow-up studies on healthy women who have done this. Dr. Sherman Silber, a pioneer of ovarian tissue cryopreservation at the Infertility Center of St. Louis, has been the most vocal advocate for this application, publishing a 2024 case series of 12 healthy women who underwent the procedure with promising short-term hormone outcomes. But 12 patients is not evidence of safety and efficacy at scale.
AMH Testing: Can You Predict When Menopause Will Hit?
Anti-Müllerian hormone is the single best predictor of reproductive lifespan, and every woman who is considering any menopause-delay intervention should get a baseline AMH test first. AMH is produced by small antral follicles in the ovary, and its level correlates directly with the number of remaining eggs. A woman aged 30 with an AMH of 0.5 ng/mL has roughly the ovarian reserve of a 42-year-old. A woman aged 40 with an AMH of 3.5 ng/mL has the reserve of a 30-year-old. Individual variation is enormous, which is exactly why knowing your number matters.
The most widely used AMH-to-menopause-timing model was published in 2023 by Dr. Sjoerd te Velde and colleagues at Utrecht University, using data from the large longitudinal Doetinchem Cohort Study. Their model predicts the age at menopause within a range of plus or minus three years, based on AMH levels measured between ages 35 and 40. A woman with AMH at the 10th percentile at age 35 can expect menopause around age 46. A woman at the 90th percentile can expect it around age 55. That is a nine-year window driven entirely by biological variation, not lifestyle — though lifestyle does exert a smaller independent effect. The test costs $50 to $150 out of pocket in most countries and is not routinely covered by insurance for healthy women. It is the single best piece of information you can have if you are deciding whether to pursue ovarian cryopreservation, enter a rapamycin trial, or simply adjust your family planning timeline.
Lifestyle Factors That Actually Shift Your Menopause Age
Smoking is the only lifestyle factor with a proven, large, and dose-dependent effect on menopause timing. Women who smoke reach menopause one to two years earlier than non-smokers, according to a 2022 meta-analysis in Maturitas that pooled data from 30 studies involving over 70,000 women. Heavy smokers — more than 20 cigarettes per day — reached menopause two to three years earlier. The mechanism is clear: polycyclic aromatic hydrocarbons in cigarette smoke are directly toxic to ovarian follicles, accelerating the rate of follicle depletion. Quitting smoking at any age slows the rate of decline, though it does not restore follicles already lost.
Body mass index has a smaller, U-shaped effect. Women with a BMI below 18.5 (underweight) and above 35 (class II obesity) both reach menopause slightly earlier — about six months to one year — compared to women in the healthy weight range. The underweight effect is thought to involve insufficient body fat for estrogen production via aromatisation in adipose tissue. The obesity effect may involve chronic low-grade inflammation that accelerates ovarian aging. Parity also matters: women who have had three or more pregnancies reach menopause six to nine months later than nulliparous women, likely because pregnancy suppresses ovulation and reduces the total number of ovulatory cycles over a lifetime.
What does not work: herbal supplements claiming to “rejuvenate” the ovaries, acupuncture for delayed menopause, or any diet that promises to prevent the menopausal transition. A 2024 systematic review in Climacteric examined 14 clinical trials of dietary interventions for ovarian aging — including soy isoflavones, resveratrol, melatonin, and vitamin D — and found no consistent effect on AMH or age at menopause. The supplement industry has latched onto menopause delay as a marketing angle with zero supporting evidence.
Uterine Transplant Research and the Ethical Questions Nobody Is Asking
Uterine transplantation is a separate conversation from ovarian aging, but it has been conflated with menopause reversal in popular media. Uterine transplants are performed for women with absolute uterine factor infertility — women who were born without a uterus or had it removed. The transplant restores the ability to carry a pregnancy but has no effect on ovarian function or hormone production. A woman who receives a uterine transplant still needs her own ovaries to produce eggs and estrogen. If her ovaries are menopausal, a uterine transplant does nothing for her menopause symptoms.
The ethical questions around actual menopause delay interventions are more nuanced. Should ovarian cryopreservation for healthy women be available on public health systems when the same resources could treat women with cancer-related infertility? Is it ethical to offer an unproven intervention like PRP (platelet-rich plasma) injections into the ovary — a procedure offered by private clinics for $2,000 to $5,000 — given that a 2025 review in Fertility and Sterility found no evidence that PRP increases ovarian function or delays menopause in any well-designed trial? The American Society for Reproductive Medicine issued a practice statement in 2024 advising against the use of PRP for ovarian agingoutside of research protocols, citing insufficient evidence. The clinics offering it continue to profit from hope.
The women who might benefit most from genuine menopause delay research are those with early menopause (before age 45) or primary ovarian insufficiency (menopause before 40). These women face decades of elevated cardiovascular risk, bone density loss, cognitive decline, and sexual health consequences. Delaying their menopause by even three to five years through ovarian cryopreservation or early-life AMH monitoring could have outsized health benefits. The current research focus on women in their late thirties and early forties — the REPLENISH trial excluded women under 38 — reflects a research bias toward studying women who are more likely to complete the protocol, not toward those who need the intervention most.
The honest bottom line: menopause reversal as most people imagine it does not exist. You cannot restart ovaries that have run out of follicles. You can slow the depletion process with rapamycin if you are in your early forties and willing to take an experimental drug. You can freeze ovarian tissue in your twenties for possible reimplantation later, paying $16,000 to $30,000 for a few extra years of hormone function. You can measure your AMH to know your biological timeline with reasonable accuracy. And you can stop smoking, because the one thing that definitely accelerates menopause is something you can control. Everything else is research or marketing, and knowing the difference is the whole point.
The menopause age page covers when menopause typically starts. Read about early menopause if you are under 45. For what you can actually do when hormone levels change, see menopause treatment options. For the full range of replacement therapies, check menopause HRT options. Visit menopause treatment for the complete site.